ArticleBreast cancer research and treatment2026

Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations.

Tal Etan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.